Last Updated: June 25, 2026

Patent: 9,809,648

✉ Email this page to a colleague

Summary for Patent: 9,809,648

Error:Operation timed out after 1001 milliseconds with 0 bytes received

Title:	Engineered anti-IL-23p19 antibodies
Abstract:	Engineered antibodies to human IL-23p19 are provided, as well as uses thereof, e.g. in treatment of inflammatory, autoimmune, and proliferative disorders.
Inventor(s):	Presta Leonard G., Beyer Brian M., Ingram Richard N., Orth Peter, Liu Yan-Hui
Assignee:	Merck Sharp & Dohme Corp.
Application Number:	US13717131
Patent Claims:	see list of patent claims

Details for Patent 9,809,648

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Sun Pharmaceutical Industries Limited	ILUMYA	tildrakizumab-asmn	Injection	761067	March 20, 2018	9,809,648	2032-12-17
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

International Patent Family for US Patent 9,809,648

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration
Argentina	065420	⤷ Start Trial
Austria	E554791	⤷ Start Trial
Australia	2008218968	⤷ Start Trial
Brazil	PI0807710	⤷ Start Trial
Canada	2678749	⤷ Start Trial
China	101687925	⤷ Start Trial
Cyprus	1112912	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.